Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference
Rein Therapeutics (NASDAQ: RNTX) announced the acceptance of their abstract for presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentation will focus on evaluating alveolar regenerative properties of Caveolin Scaffolding Peptides (CSD) in 3D alveolospheres from IPF and normal donor lung samples.
The poster presentation (P1463) is scheduled for Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET, as part of Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX) ha annunciato l'accettazione del loro abstract per la presentazione al American Thoracic Society (ATS) 2025 International Conference che si terrà a San Francisco dal 18 al 21 maggio 2025. La presentazione si concentrerà sulla valutazione delle proprietà rigenerative alveolari dei Peptidi Caveolin Scaffolding (CSD) in alveolosfere 3D ottenute da campioni polmonari di pazienti con IPF e donatori normali.
La presentazione poster (P1463) è programmata per lunedì 19 maggio 2025, alle 11:30 PT / 14:30 ET, nell'ambito della Sessione B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX) anunció la aceptación de su resumen para presentación en la Conferencia Internacional 2025 de la American Thoracic Society (ATS) en San Francisco, del 18 al 21 de mayo de 2025. La presentación se centrará en evaluar las propiedades regenerativas alveolares de los Péptidos Caveolin Scaffolding (CSD) en alveolosferas 3D provenientes de muestras pulmonares de pacientes con FPI y donantes normales.
La presentación en póster (P1463) está programada para el lunes 19 de mayo de 2025, a las 11:30 AM PT / 2:30 PM ET, como parte de la Sesión B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX)는 2025년 5월 18일부터 21일까지 샌프란시스코에서 열리는 미국 흉부학회(ATS) 2025 국제 학술대회에서 초록이 채택되었음을 발표했습니다. 발표는 특발성 폐섬유증(IPF) 및 정상 기증자 폐 샘플에서 유래한 3D 폐포구에서 Caveolin Scaffolding Peptides(CSD)의 폐포 재생 특성 평가에 중점을 둘 예정입니다.
포스터 발표(P1463)는 2025년 5월 19일 월요일 오전 11시 30분 PT / 오후 2시 30분 ET에 예정되어 있으며, 세션 B75: 폐 손상 및 섬유증에서 세포 노화, 면역 이상 및 대사 조절을 겨냥한 연구의 일환입니다.
Rein Therapeutics (NASDAQ : RNTX) a annoncé l'acceptation de leur résumé pour présentation lors de la Conférence Internationale 2025 de l'American Thoracic Society (ATS) à San Francisco, du 18 au 21 mai 2025. La présentation portera sur l’évaluation des propriétés régénératrices alvéolaires des peptides Caveolin Scaffolding (CSD) dans des alvéolosphères 3D issues d’échantillons pulmonaires de patients atteints de fibrose pulmonaire idiopathique (FPI) et de donneurs normaux.
La présentation sous forme de poster (P1463) est prévue le lundi 19 mai 2025 à 11h30 PT / 14h30 ET, dans le cadre de la session B75 : Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX) gab die Annahme ihres Abstracts für eine Präsentation auf der American Thoracic Society (ATS) 2025 International Conference in San Francisco vom 18. bis 21. Mai 2025 bekannt. Die Präsentation wird sich auf die Bewertung der alveolären regenerativen Eigenschaften von Caveolin Scaffolding Peptides (CSD) in 3D-Alveolosphären aus Lungenproben von IPF-Patienten und normalen Spendern konzentrieren.
Die Posterpräsentation (P1463) ist für Montag, den 19. Mai 2025, um 11:30 Uhr PT / 14:30 Uhr ET geplant und findet im Rahmen der Sitzung B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis statt.
- None.
- None.
Details of the poster presentation are as follows:
Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples
Poster #: P1463
Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis
Date & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis is anticipated to be initiated in the first half of this year. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the
Rein Investor Relations & Media Contact:
Argot Partners
rein@argotpartners.com
212-600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/rein-therapeutics-announces-abstract-accepted-for-presentation-at-the-american-thoracic-society-2025-international-conference-302439327.html
SOURCE Rein Therapeutics, Inc.
FAQ
What will Rein Therapeutics (RNTX) present at the ATS 2025 Conference?
When and where is RNTX's presentation at the ATS 2025 Conference?
What therapeutic areas does Rein Therapeutics (RNTX) focus on?
Which session will feature RNTX's research at the ATS 2025 Conference?
